Minerva Neurosciences (NERV) Change in Cash (2013 - 2026)
Minerva Neurosciences posted quarterly Change in Cash of -$49.6 million for Q1 2026, down 1119.12% year-on-year from $4.9 million in Q1 2025, and down 170.9% on a QoQ basis from $70.0 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Change in Cash data on file, last reported at -$49.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Cash fell 1119.12% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at $15.4 million (up 187.69% YoY), and the FY2025 full-year result was $60.9 million, up 411.7% from the prior year.
- Change in Cash for Q1 2026 stood at -$49.6 million, down from $70.0 million in the prior quarter.
- Across five years, Change in Cash topped out at $70.0 million in Q4 2025 and bottomed at -$49.6 million in Q1 2026.
- The 5-year median for Change in Cash is -$4.4 million (2024), against an average of -$1.7 million.
- The widest annual swing landed in 2024, when Change in Cash plunged 5180.68%; it then soared 1455.1% in 2025.
- A 5-year view of Change in Cash shows it stood at -$4.1 million in 2022, then slumped by 45.2% to -$6.0 million in 2023, then increased by 13.76% to -$5.2 million in 2024, then jumped by 1455.1% to $70.0 million in 2025, then tumbled by 170.9% to -$49.6 million in 2026.
- The last three Change in Cash figures came in at -$49.6 million (Q1 2026), $70.0 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -49.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.64 Mn |
| Dec 31, 2025 | 70.02 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Dec 31, 2023 | -5.99 Mn |
| Sep 30, 2023 | -4.89 Mn |
| Jun 30, 2023 | 15.82 Mn |
| Mar 31, 2023 | -115,407.00 |
| Dec 31, 2022 | -4.13 Mn |
| Sep 30, 2022 | -9.53 Mn |
| Jun 30, 2022 | -5.19 Mn |
| Mar 31, 2022 | -5.81 Mn |
| Dec 31, 2021 | -4.83 Mn |
| Sep 30, 2021 | -8.63 Mn |
| Jun 30, 2021 | -5.92 Mn |
| Mar 31, 2021 | 54.78 Mn |
| Dec 31, 2020 | -7.16 Mn |
| Sep 30, 2020 | 263,758.00 |
| Jun 30, 2020 | 2.22 Mn |
| Mar 31, 2020 | 8.62 Mn |
| Dec 31, 2019 | -16.49 Mn |
| Sep 30, 2019 | 10.06 Mn |
| Jun 30, 2019 | -2.76 Mn |
| Mar 31, 2019 | -19.63 Mn |
| Dec 31, 2018 | -37.06 Mn |
| Sep 30, 2018 | 18.61 Mn |
| Jun 30, 2018 | 23.56 Mn |
| Mar 31, 2018 | 19.09 Mn |
| Dec 31, 2017 | -10.20 Mn |
| Sep 30, 2017 | -13.94 Mn |
| Jun 30, 2017 | -18.70 Mn |
| Mar 31, 2017 | -14.09 Mn |
| Dec 31, 2016 | -8.87 Mn |
| Sep 30, 2016 | 3.18 Mn |
| Jun 30, 2016 | 53.85 Mn |
| Mar 31, 2016 | 20.54 Mn |
| Dec 31, 2015 | -2.55 Mn |
| Sep 30, 2015 | -4.90 Mn |
| Jun 30, 2015 | -30.47 Mn |
| Mar 31, 2015 | 33.66 Mn |
| Dec 31, 2014 | -5.09 Mn |
| Sep 30, 2014 | 23.16 Mn |
| Jun 30, 2014 | -1.66 Mn |
| Mar 31, 2014 | 322,914.00 |
| Dec 31, 2013 | 718,061.00 |
| Sep 30, 2013 | -381,703.00 |